vs
Limbach Holdings, Inc.（LMB）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
Limbach Holdings, Inc.的季度营收约是再鼎医药的1.5倍（$186.9M vs $127.1M），Limbach Holdings, Inc.同比增速更快（30.1% vs 17.1%），Limbach Holdings, Inc.自由现金流更多（$27.9M vs $-26.7M），过去两年Limbach Holdings, Inc.的营收复合增速更高（25.3% vs 20.8%）
林巴赫航空发动机是一家由中资控股、总部位于德国的企业，主营航空发动机的研发与制造业务，在航空动力装备领域拥有成熟的生产技术与行业经验。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
LMB vs ZLAB — 直观对比
营收规模更大
LMB
是对方的1.5倍
$127.1M
营收增速更快
LMB
高出13.0%
17.1%
自由现金流更多
LMB
多$54.6M
$-26.7M
两年增速更快
LMB
近两年复合增速
20.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $186.9M | $127.1M |
| 净利润 | $12.3M | — |
| 毛利率 | 25.7% | 51.0% |
| 营业利润率 | 9.4% | -54.6% |
| 净利率 | 6.6% | — |
| 营收同比 | 30.1% | 17.1% |
| 净利润同比 | 25.0% | — |
| 每股收益（稀释后） | $1.01 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LMBZLAB
| Q4 25 | $186.9M | $127.1M | ||
| Q3 25 | $184.6M | $115.4M | ||
| Q2 25 | $142.2M | $109.1M | ||
| Q1 25 | $133.1M | $105.7M | ||
| Q4 24 | $143.7M | $108.5M | ||
| Q3 24 | $133.9M | $101.8M | ||
| Q2 24 | $122.2M | $100.1M | ||
| Q1 24 | $119.0M | $87.1M |
净利润LMBZLAB
| Q4 25 | $12.3M | — | ||
| Q3 25 | $8.8M | $-36.0M | ||
| Q2 25 | $7.8M | $-40.7M | ||
| Q1 25 | $10.2M | $-48.4M | ||
| Q4 24 | $9.8M | — | ||
| Q3 24 | $7.5M | $-41.7M | ||
| Q2 24 | $6.0M | $-80.3M | ||
| Q1 24 | $7.6M | $-53.5M |
毛利率LMBZLAB
| Q4 25 | 25.7% | 51.0% | ||
| Q3 25 | 24.2% | 59.5% | ||
| Q2 25 | 28.0% | 60.6% | ||
| Q1 25 | 27.6% | 63.6% | ||
| Q4 24 | 30.3% | 61.5% | ||
| Q3 24 | 27.0% | 64.1% | ||
| Q2 24 | 27.4% | 64.9% | ||
| Q1 24 | 26.1% | 61.4% |
营业利润率LMBZLAB
| Q4 25 | 9.4% | -54.6% | ||
| Q3 25 | 7.2% | -42.3% | ||
| Q2 25 | 7.5% | -50.3% | ||
| Q1 25 | 5.9% | -53.3% | ||
| Q4 24 | 9.1% | -62.6% | ||
| Q3 24 | 8.1% | -66.6% | ||
| Q2 24 | 6.7% | -76.0% | ||
| Q1 24 | 5.5% | -80.7% |
净利率LMBZLAB
| Q4 25 | 6.6% | — | ||
| Q3 25 | 4.8% | -31.2% | ||
| Q2 25 | 5.5% | -37.3% | ||
| Q1 25 | 7.7% | -45.8% | ||
| Q4 24 | 6.9% | — | ||
| Q3 24 | 5.6% | -40.9% | ||
| Q2 24 | 4.9% | -80.2% | ||
| Q1 24 | 6.4% | -61.4% |
每股收益（稀释后）LMBZLAB
| Q4 25 | $1.01 | $-0.05 | ||
| Q3 25 | $0.73 | $-0.03 | ||
| Q2 25 | $0.64 | $-0.04 | ||
| Q1 25 | $0.85 | $-0.04 | ||
| Q4 24 | $0.81 | $-0.09 | ||
| Q3 24 | $0.62 | $-0.04 | ||
| Q2 24 | $0.50 | $-0.08 | ||
| Q1 24 | $0.64 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $11.3M | $689.6M |
| 总债务越低越好 | $30.5M | — |
| 股东权益账面价值 | $195.7M | $715.5M |
| 总资产 | $381.1M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.16× | — |
8季度趋势，按日历期对齐
现金及短期投资LMBZLAB
| Q4 25 | $11.3M | $689.6M | ||
| Q3 25 | $9.8M | $717.2M | ||
| Q2 25 | $38.9M | $732.2M | ||
| Q1 25 | $38.1M | $757.3M | ||
| Q4 24 | $44.9M | $779.7M | ||
| Q3 24 | $51.2M | $616.1M | ||
| Q2 24 | $59.5M | $630.0M | ||
| Q1 24 | $48.2M | $650.8M |
总债务LMBZLAB
| Q4 25 | $30.5M | — | ||
| Q3 25 | $56.3M | — | ||
| Q2 25 | $28.4M | — | ||
| Q1 25 | $23.7M | — | ||
| Q4 24 | $23.6M | — | ||
| Q3 24 | $20.5M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $19.4M | — |
股东权益LMBZLAB
| Q4 25 | $195.7M | $715.5M | ||
| Q3 25 | $181.6M | $759.9M | ||
| Q2 25 | $170.5M | $791.7M | ||
| Q1 25 | $161.1M | $810.8M | ||
| Q4 24 | $153.5M | $840.9M | ||
| Q3 24 | $142.2M | $667.7M | ||
| Q2 24 | $133.0M | $704.2M | ||
| Q1 24 | $125.5M | $762.2M |
总资产LMBZLAB
| Q4 25 | $381.1M | $1.2B | ||
| Q3 25 | $409.1M | $1.2B | ||
| Q2 25 | $343.0M | $1.2B | ||
| Q1 25 | $336.4M | $1.2B | ||
| Q4 24 | $352.1M | $1.2B | ||
| Q3 24 | $324.4M | $985.3M | ||
| Q2 24 | $303.9M | $987.4M | ||
| Q1 24 | $289.2M | $988.4M |
负债/权益比LMBZLAB
| Q4 25 | 0.16× | — | ||
| Q3 25 | 0.31× | — | ||
| Q2 25 | 0.17× | — | ||
| Q1 25 | 0.15× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 0.15× | — | ||
| Q1 24 | 0.15× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.1M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $27.9M | $-26.7M |
| 自由现金流率自由现金流/营收 | 14.9% | -21.0% |
| 资本支出强度资本支出/营收 | 0.1% | 0.5% |
| 现金转化率经营现金流/净利润 | 2.29× | — |
| 过去12个月自由现金流最近4个季度 | $41.9M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流LMBZLAB
| Q4 25 | $28.1M | $-26.0M | ||
| Q3 25 | $13.3M | $-32.0M | ||
| Q2 25 | $2.0M | $-31.0M | ||
| Q1 25 | $2.2M | $-61.7M | ||
| Q4 24 | $19.3M | $-55.8M | ||
| Q3 24 | $4.9M | $-26.8M | ||
| Q2 24 | $16.5M | $-42.2M | ||
| Q1 24 | $-3.9M | $-90.1M |
自由现金流LMBZLAB
| Q4 25 | $27.9M | $-26.7M | ||
| Q3 25 | $12.8M | $-35.0M | ||
| Q2 25 | $1.2M | $-33.9M | ||
| Q1 25 | $11.0K | $-63.2M | ||
| Q4 24 | $18.0M | $-58.4M | ||
| Q3 24 | $4.6M | $-28.2M | ||
| Q2 24 | $13.2M | $-42.9M | ||
| Q1 24 | $-6.5M | $-91.1M |
自由现金流率LMBZLAB
| Q4 25 | 14.9% | -21.0% | ||
| Q3 25 | 7.0% | -30.4% | ||
| Q2 25 | 0.8% | -31.1% | ||
| Q1 25 | 0.0% | -59.9% | ||
| Q4 24 | 12.5% | -53.8% | ||
| Q3 24 | 3.4% | -27.7% | ||
| Q2 24 | 10.8% | -42.9% | ||
| Q1 24 | -5.5% | -104.5% |
资本支出强度LMBZLAB
| Q4 25 | 0.1% | 0.5% | ||
| Q3 25 | 0.3% | 2.6% | ||
| Q2 25 | 0.6% | 2.6% | ||
| Q1 25 | 1.7% | 1.5% | ||
| Q4 24 | 0.9% | 2.4% | ||
| Q3 24 | 0.3% | 1.3% | ||
| Q2 24 | 2.7% | 0.7% | ||
| Q1 24 | 2.1% | 1.1% |
现金转化率LMBZLAB
| Q4 25 | 2.29× | — | ||
| Q3 25 | 1.52× | — | ||
| Q2 25 | 0.26× | — | ||
| Q1 25 | 0.22× | — | ||
| Q4 24 | 1.96× | — | ||
| Q3 24 | 0.66× | — | ||
| Q2 24 | 2.77× | — | ||
| Q1 24 | -0.52× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LMB
| Owner Direct Relationships Segment | $145.0M | 78% |
| General Contractor Construction Manager Relationships Segment | $41.9M | 22% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
